HARBIN PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.01 CNY | +6.36% |
|
+7.89% | -10.15% |
| 04-25 | Harbin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-11 | Harbin Pharma to Upgrade Subsidiary's Production Base for 50 Million Yuan | MT |
| Sales 2022 | 13.81B 1.91B 152B | Sales 2023 | 15.46B 2.13B 170B | Capitalization | 8.45B 1.17B 93.05B |
|---|---|---|---|---|---|
| Net income 2022 | 464M 64.03M 5.11B | Net income 2023 | 395M 54.51M 4.35B | EV / Sales 2022 | 0.53 x |
| Net cash position 2022 | 284M 39.21M 3.13B | Net cash position 2023 | 1.2B 166M 13.26B | EV / Sales 2023 | 0.47 x |
| P/E ratio 2022 |
16.7
x | P/E ratio 2023 |
20.9
x | Employees | 9,853 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 48.46% |
More Fundamentals
* Assessed data
More news
| 1 day | +6.36% | ||
| 1 week | +7.89% | ||
| Current month | +2.03% | ||
| 1 month | +2.73% | ||
| 3 months | -3.22% | ||
| 6 months | -15.92% | ||
| Current year | -10.15% |
1 week
2.76
3.04
1 month
2.723.04
Current year
2.413.46
1 year
2.413.90
3 years
2.413.95
5 years
2.386.53
10 years
2.3813.23
| Managers | Title | Age | Since |
|---|---|---|---|
Bo Liu
DFI | Director of Finance/CFO | 61 | 25/09/08 |
Kun Yu Ma
IRC | Investor Relations Contact | 43 | 30/04/14 |
Xiao Dong Meng
SEC | Corporate Secretary | 52 | 23/12/04 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiao Dong Meng
SEC | Corporate Secretary | 52 | 23/12/04 |
Ai Dong Lou
BRD | Director/Board Member | 58 | 07/01/21 |
Bo Liu
DFI | Director of Finance/CFO | 61 | 25/09/08 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 3.01 | +6.36% | 81,524,140 |
| 25/04/24 | 2.83 | +0.35% | 22,197,520 |
| 24/04/24 | 2.82 | +0.36% | 20,626,590 |
| 23/04/24 | 2.81 | +1.44% | 24,059,310 |
| 22/04/24 | 2.77 | -0.72% | 22,653,610 |
End-of-day quote Shanghai S.E., April 25, 2024
More quotes
Harbin Pharmaceutical Group Co is a China-based company mainly engaged in pharmaceutical research and development. The Company's main businesses are innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals, covering the business sectors of antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The Companyâs main products include calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, Xingaizhonggai high calcium tablets, etc.
Sector
Pharmaceuticals
Calendar
29/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -10.15% | 1.05B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 600664 Stock
